|
시장보고서
상품코드
2102501
심근경색 시장 규모, 점유율 및 성장 분석 : 유형별, 진단별, 치료별, 약제 클래스별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Myocardial Infarction Market Size, Share, and Growth Analysis, By Type, By Diagnosis(Cardiac Biomarker Tests), By Treatment, By Drug Class, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 심근경색 시장 규모는 2024년에 26억 7,000만 달러로 평가되며, 2025년 28억 2,000만 달러에서 2033년까지 152억 8,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 5.5%로 성장할 것으로 전망되고 있습니다.
전 세계 심근경색 시장은 전 세계 사망 원인 1위라는 상황에 힘입어, 급성 관상동맥 사건을 치료하기 위한 의약품, 중재적 의료기기, 진단 서비스를 통합한 시장입니다. 고령화 및 생활 습관과 관련된 위험 요인으로 인한 발병률 증가로 인해 새로운 항혈소판제나 약물 방출형 스텐트의 도입 등 제품 혁신이 가속화되고 있습니다. 디지털 헬스의 발전이 시장 상황을 변화시키고 있으며, 전자 건강 기록 및 실시간 모니터링을 통해 조기 발견을 촉진하는 확장 가능한 솔루션이 가능해졌습니다. 특히 임상 데이터를 분석하여 진단을 신속화하는 AI 애플리케이션이 주목받고 있습니다. 이러한 변화로 인해 임상 워크플로우의 병목 현상이 해소되고, 해당 분야에 대한 투자가 촉진되고 있습니다. 또한 보험 환급 제도 개혁으로 인해 초점이 급성기 의료에서 장기적인 위험 관리로 확대되면서, 혁신적인 솔루션을 위한 보다 광범위한 시장 기회가 창출되고 있습니다.
전 세계 심근경색 시장의 성장 요인
고령화의 진행은 심근경색 유병률 증가에 크게 기여하고 있으며, 그 결과 급성기 의료, 약물 치료 및 발병 후 재활 서비스에 대한 지속적인 수요를 창출하고 있습니다. 이에 대응하여 의료 시스템에서는 전문적인 심장 질환 치료 부문의 강화와 첨단 치료용 의료기기에 대한 투자가 진행되고 있으며, 이러한 조치들이 이용 확대와 지속적인 혁신을 통해 시장 발전을 지원하고 있습니다. 또한 고령층의 심혈관 질환 위험 요인에 대한 인식이 높아지면서 예방적 선별 검진 활동이 촉진되고 있으며, 이에 따라 진단 검사 및 조기 치료 개입이 증가하고 있습니다. 이는 지속적인 환자 모니터링 활동을 지원하며 시장의 추가적인 확장을 촉진하고 있습니다.
전 세계 심근경색 시장의 제약 요인
전 세계 심근경색 치료 시장은 혁신적인 스텐트나 생물제제 등 첨단 치료법에 수반되는 높은 비용으로 인해 현저한 제약에 직면해 있습니다. 이러한 고가 정책은 의료 시스템과 환자 모두에게 막대한 재정적 부담을 안겨주며, 보험사의 엄격한 처방약 리스트 제한 및 사전 승인 절차 도입으로 이어지고 있습니다. 이러한 조치는 종종 치료 시작을 지연시키고, 신기술에 대한 시장 접근을 제한하게 됩니다. 그 결과, 의료 서비스 제공자들은 고부가가치 제품 대신 이미 확립된 저비용 대체품을 선택하기도 하며, 이는 시장 전체의 수요를 억제하는 요인이 되고 있습니다. 또한 이러한 새로운 치료법의 장기적인 비용 대비 효과에 대한 불확실성이 보험 급여 적용 노력을 저해하고, 다양한 지역에서의 도입을 제한하고 있습니다.
전 세계 심근경색 시장 동향
전 세계 심근경색 시장에서는 유전체 프로파일링의 발전으로 인해 개별 유전적 위험 요인에 기반한 맞춤형 치료가 가능해짐에 따라 개인 맞춤형 유전체 치료로의 큰 전환이 진행되고 있습니다. 이러한 범용 치료법에서 정밀 의학으로의 전환은 환자의 예후를 개선할 뿐만 아니라 불필요한 치료를 최소화하는 결과로 이어집니다. 제약사들은 동반 진단을 포함한 파이프라인 개발에 점점 더 집중하고 있으며, 생명공학 기업 및 학술기관과 제휴하여 혁신적인 솔루션을 창출하고 있습니다. 이러한 전략적 포지셔닝을 통해 전문적인 치료법에 프리미엄 가격을 책정할 수 있게 되었으며, 이는 전 세계 심근경색 치료 분야에서 표적을 고도로 선별한 치료법으로의 지속적인 추세를 반영하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 심근경색 시장 규모 : 유형별
세계의 심근경색 시장 규모 : 진단별
세계의 심근경색 시장 규모 : 치료별
세계의 심근경색 시장 규모 : 약제 클래스별
세계의 심근경색 시장 규모 : 최종사용자별
세계의 심근경색 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.08.05Global Myocardial Infarction Market size was valued at USD 2.67 Billion in 2024 and is poised to grow from USD 2.82 Billion in 2025 to USD 15.28 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).
The global myocardial infarction market integrates pharmaceuticals, interventional devices, and diagnostic services to address acute coronary events, driven by its status as a leading cause of global mortality. The rising incidence, attributed to aging populations and lifestyle-related risk factors, has prompted accelerated product innovation, including the introduction of novel antiplatelet agents and drug-eluting stents. Digital health advancements are transforming the landscape, enabling scalable solutions that enhance early detection through electronic health records and real-time monitoring, particularly with AI applications that analyze clinical data for faster diagnostics. This shift is reducing bottlenecks in clinical workflows and fostering investment in the sector. Furthermore, reimbursement reforms are expanding focus from acute care to long-term risk management, creating wider market opportunities for innovative solutions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Myocardial Infarction market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Myocardial Infarction Market Segments Analysis
Global myocardial infarction market is segmented by type, diagnosis, treatment, drug class, end user and region. Based on type, the market is segmented into ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Based on diagnosis, the market is segmented into Electrocardiogram (ECG), Cardiac Biomarker Tests, Coronary Angiography, Echocardiography and Others. Based on treatment, the market is segmented into Pharmacological Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG) and Other Interventional Procedures. Based on drug class, the market is segmented into Antiplatelet Agents, Anticoagulants, Thrombolytic Agents, Beta-Blockers, ACE Inhibitors & ARBs, Statins and Others. Based on end user, the market is segmented into Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers (ASCs) and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Myocardial Infarction Market
The rise in the aging population contributes significantly to the growing prevalence of myocardial infarction, thereby driving a persistent need for acute care, medication, and rehabilitation services post-event. In response, healthcare systems are enhancing their specialized cardiac units and investing in advanced therapeutic devices, which boosts market development through increased use and continuous innovation. Moreover, heightened awareness of cardiovascular risk factors among older adults promotes preventive screening initiatives, leading to an uptick in diagnostic procedures and early treatment interventions, which in turn support ongoing patient monitoring efforts and further propel market expansion.
Restraints in the Global Myocardial Infarction Market
The global market for myocardial infarction treatments faces notable constraints due to the high costs associated with advanced therapies, such as innovative stents and biologic agents. This premium pricing creates substantial financial strain on both healthcare systems and patients, leading payers to implement strict formulary limitations and necessitate prior authorization processes. These measures often result in delays in treatment initiation and restrict market access for newer technologies. As a result, healthcare providers may choose to use established, lower-cost alternatives instead of high-value products, restraining overall market demand. Furthermore, uncertainties regarding the long-term cost-effectiveness of these novel interventions hinder reimbursement efforts, limiting their adoption in various areas.
Market Trends of the Global Myocardial Infarction Market
The Global Myocardial Infarction market is experiencing a significant shift towards personalized genomic therapies, as advances in genomic profiling allow for tailored treatments based on individual genetic risk factors. This transition from generic interventions to precision medicine not only enhances patient outcomes but also minimizes unnecessary treatments. Pharmaceutical companies are increasingly focusing on developing pipelines that include companion diagnostics, partnering with biotech firms and academic institutions to create innovative solutions. This strategic positioning enables them to command premium pricing for specialized therapies, reflecting a sustainable trend towards highly targeted interventions in the myocardial infarction landscape globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Myocardial Infarction Market Size by Type & CAGR (2026-2033)
- Market Overview
- ST-Elevation Myocardial Infarction (STEMI)
- Non-ST-Elevation Myocardial Infarction (NSTEMI)
Global Myocardial Infarction Market Size by Diagnosis & CAGR (2026-2033)
- Market Overview
- Electrocardiogram (ECG)
- Cardiac Biomarker Tests
- Coronary Angiography
- Echocardiography
- Others
Global Myocardial Infarction Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Pharmacological Therapy
- Percutaneous Coronary Intervention (PCI)
- Coronary Artery Bypass Grafting (CABG)
- Other Interventional Procedures
Global Myocardial Infarction Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Antiplatelet Agents
- Anticoagulants
- Thrombolytic Agents
- Beta-Blockers
- ACE Inhibitors & ARBs
- Statins
- Others
Global Myocardial Infarction Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Cardiac Care Centers
- Ambulatory Surgical Centers (ASCs)
- Specialty Clinics
Global Myocardial Infarction Market Size & CAGR (2026-2033)
- North America (Type, Diagnosis, Treatment, Drug Class, End User)
- US
- Canada
- Europe (Type, Diagnosis, Treatment, Drug Class, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Diagnosis, Treatment, Drug Class, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Diagnosis, Treatment, Drug Class, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Diagnosis, Treatment, Drug Class, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi Aventis US LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Daiichi Sankyo Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apotex Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chiesi Farmaceutici SpA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
